期刊文献+

尤文肉瘤EWS-FLI1蛋白HLA-A2.1限制性CTL表位的预测、筛选及鉴定 被引量:4

Prediction,screening,and identification of HLA-A2.1-restricted CTL epitopes derived from Ewing's sarcoma EWS-FLI1 fusion protein
原文传递
导出
摘要 目的预测、筛选及合成尤文肉瘤EWS-FLI1蛋白HLA-A2.1限制性细胞毒性T淋巴细胞(Cytotoxic T Lymphocyte,CTL)表位,初步鉴定EWS-FLI1表位肽。方法综合运用BIMAS、SYFPEITHI、Predep和IEDB方案对EWS-FLI1蛋白进行HLA-A^*0201限制性CTL表位的预测,应用多项式方案、量化基序方案对预测的CTL表位进行筛选,并将筛选的CTL表位与HLA-A^*0201分子进行动力学模拟,应用标准Fmoc方案合成CTL表位肽;通过表位多肽刺激CTL释放颗粒溶素的检测,以及靶细胞杀伤实验验证表位多肽的免疫效应。结果综合预测得出了8个可能的表位肽,进一步筛选确定其中4个肽为候选合成表位,应用分子动力模拟初步验证了4个候选表位肽与HLA-A2.1分子的结合力,合成的各条肽经色谱分析纯度均在98%以上,经质谱分析各肽的分子量测定值与理论值相符,颗粒溶素释放实验及靶细胞杀伤实验证实了筛选的表位均能产生刺激效应,其中,表位肽QIQLWQFLL(EWS-FLI1 304)的刺激效应最为显著。结论综合运用多个方案可提高预测效率,分子动力学模拟可初步验证表位肽与HLA-A^*0201的结合力,所合成的多肽为高纯度肽,通过免疫学实验初步鉴定了EWS-FLI1的表位。 EWS-FLI1 fusion protein expressed in Ewing's sarcoma(ES) is a new therapeutical target for ES treatment.The aim of this study is to predict and screen the HLA-A2.1-restricted CTL epitopes of Ewing's sarcoma EWS-FLI1 fusion protein,and to primarily identify the predicted HLA-A2.1-restricted CTL epitope candidates.The HLA-A2.1-restricted CTL epitopes of EWS-FLI1 fusion protein were synthetically predicted by BIMAS,SYFPEITHI,Predep and IEDB methods,and then screened by the polynomial and quantitative motif method combined with supermotif prediction method as well.Docking of the screened peptides and HLA-A2.1 was observed by molecular dynamics simulation,while all peptides were synthesized with standard Fmoc strategy.After being stimulated by peptides,the CTL granulysin release test and the test of killing effects of CTL on target cells were performed to validate the immunological effects of screened epitopes.Eight CTL epitopes were predicted,among which 4 peptides were the candidates to be synthesized.The candidates docking with HLA-A2.1 were primarily validated by molecular dynamics simulation.All synthesized peptides were detected beyond 98%in purity by reverse phase high performance liquid chromatography(RP-HPLC) and the values of molecular weight of them were conformed to match their theoretical values by mass spectrometry(MS).The granulysin release test and killing effects of CTL on target cells confirmed that all screened peptides were able to induce the cytotoxic effect of T lymphocytes.Moreover,peptide QIQLWQFLL(EWS-FLI1 304) was the most effective epitope of EWS-FLI1. All the results demonstrates that our work efficiently predict,screened,and identified the peptides of EWS-FL11.
出处 《免疫学杂志》 CAS CSCD 北大核心 2010年第1期10-15,共6页 Immunological Journal
基金 国家自然科学基金资助项目(30760254)
关键词 CTL表位 多肽合成 尤文肉瘤 EWS-FLI1 分子动力模拟 CTL epitope Polypeptide synthesis Ewing's sarcoma EWS-FLI1 Molecular dynamics simulation
  • 相关文献

参考文献12

  • 1R odriguez Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future[J]. Med Pediatr Oncol, 2003, 40 (5): 276-287.
  • 2Grier HE, Krailo MD, Tarbell N J, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone[J]. N Engl J Med, 2003,348(8):694-701.
  • 3Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing' s sarcoma family of tumors [J]. J Clin Oncol, 2005,23(19):4354-4362.
  • 4Chansky HA, Barahmand Pour F, Mei Q, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro [J]. J Orthop Res, 2004, 22(4):910-917.
  • 5Hu Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor gTowth in a murine model of metastatic Ewing' s Sarcoma[J]. Cancer Res, 2005,65(19):8984-8992.
  • 6郭义,郭卫,汤小东,高占成,何湘君.尤文肉瘤基因免疫治疗的研究[J].中华实验外科杂志,2004,21(7):848-851. 被引量:8
  • 7Tirado OM, Mateo Lozano S, Villar J, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's Sareoma cells[J]. Cancer Res, 2006, 66 (20): 9937-9947.
  • 8Gulukota K, Sidney J, Sette A, et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules [J]. J Mol Biol, 1997,267 (5): 1258-1267.
  • 9Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides base on independent binding of individual peptide side-chains [J]. J Immunol, 1994,152(1):163-175.
  • 10Lim JS, Kim S, Lee HG, et al. Selection of peptides that bind to the HLA-A2.1 molecnle by molecular modeling [J]. Mol Immunol, 1996, 33 (2): 2212-2230.

二级参考文献15

  • 1郭义,郭卫,汤小东,高占成,何湘君.尤文肉瘤基因免疫治疗的研究[J].中华实验外科杂志,2004,21(7):848-851. 被引量:8
  • 2林治华,王槐亮,唐艳,吴玉章.计算机辅助筛选酪氨酸激酶相关蛋白TRP-2 CTL模拟表位[J].化学学报,2007,65(8):760-764. 被引量:1
  • 3章卫平,曹雪涛,张明徽,黄欣,朱学军,叶天星.GM-CSF重组腺病毒扩增的骨髓树突状细胞体外经肿瘤抗原刺激后诱导抗肿瘤免疫应答[J].中国免疫学杂志,1997,13(1):29-33. 被引量:14
  • 4Rodriguez-Galindo, C.; Spunt, S. L.; Pappo, A. S. Med. Pediatr. Oncol. 2003, 40, 276.
  • 5Grier, H. E.; Krailo, M. D.; Tarbell, N. J.; Link, M. P.;Fryer, C. J.; Pritchard, D. J.; Gebhardt, M. C.; Dickman, P. S.; Perlman, E. J.; Meyers, P. A.; Donaldson, S. S.; Moore, S.; Rausen, A. R.; Vietti, T. J.; Miser, J. S. N. Engl. J. Med. 2003, 348, 694.
  • 6Barker, L. M.; Pendergrass, T. W.; Sanders, J. E.; Hawkins, D. S. J. Clin. Oncol. 2005, 23, 4354.
  • 7Chansky, H. A.; Barahmand-Pour, F. Mei, Q.; Kahn- Farooqi, W.; Zielinska-Kwiatkowska, A.; Blackburn, M.; Chansky, K.; Conrad, E. U. 3rd.; Bruckner, J. D.; Greenlee, T. K.; Yang, L. J. Orthop. Res. 2004, 22, 910.
  • 8Hu-Lieskovan, S.; Heidel, J. D.; Bartlett, D. W.; Davis, M. E.; Triche, T. J. Cancer Res. 2005, 65(19), 8984.
  • 9Tirado, O. M.; Mateo-Lozano, S.; Villar, J.; Dettin, L. E.; Llort, A.; Gallego, S.; Ban, J.; Kovar, H.; Notario, V. Cancer Res. 2006, 66(20), 9937.
  • 10Rener, M.; Claesson, M. H.; Bregenholt, S.; Ropke, M. Exp. Clin. lmmunogenet. 1996, 13(1), 30.

共引文献9

同被引文献43

  • 1熊建光,程正位,吴娟,袁婷,杜金龙.消化道恶性肿瘤患者血清微量元素水平研究[J].现代预防医学,2012,39(22):5918-5919. 被引量:9
  • 2沈菁,潘敏,杜春桃.探讨微量元素铜、锌、铁与恶性肿瘤的关系[J].海南医学,2005,16(4):16-17. 被引量:9
  • 3李琼,张卫华.微量元素与恶性肿瘤关系的探讨[J].实用预防医学,2005,12(5):1134-1135. 被引量:16
  • 4Baas EJ, Van Santen HM, Kleijmeer MJ, et al. Peptide-induced stabilization and intracellular localization of empty HLA class Ⅰ complexes [J].J Exp Med, 1992, 176:147-156.
  • 5Kondo A, Sidney J, Southwood S, et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class Ⅰ molecules [J]. Immunol, 1995,155: 4307-4312.
  • 6Rock KL, Gramm C, Benacerraf B. Low temperature and peptides favor the formation of class Ⅰ heterodimers on RMA-S cells at the cell surface [J]. PNAS, 1991, 88: 4200-4204.
  • 7Howell D,Levitt JM,Foster PA,et al. Heterogeneity of RMA-S cell line: derivatives of RMA-S cells lacking H2-Kb and H2-Db expression [J]. Immunogenetics, 2000, 52(1/2): 150-154.
  • 8Anderson KS, Alexander J, Wei M, et al. Intracellular transport of class t MHC molecules in antigen processing mutant cell lines[J], Immunol, 1993, 151: 3407-3419.
  • 9Cheung YK, Cheng SC, Sin FW, et al. Investigation of immunogenic T-cell epitopes in SARS virus nucleocapsid protein and their role in the prevention and treatment of SARS infection[J]. Hong Kong Med J, 2008, 14 (4):27-30.
  • 10Erlich H, Lee JS, Petersen JW,et al. Molecular analysis of HLA class Ⅰ and class Ⅱ antigen loss mutants reveals a homozygous deletion of the DR, DQ, and part of the DP region: implications for class Ⅱ gene order [J].Hum Immunol, 1986, 16:205-219.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部